Hypothesis

Expressing a low‑conductance, red‑shifted human opsin (e.g., melanopsin variant) directly in surviving rods during the early phase of retinal degeneration provides tonic, sub‑threshold light‑driven signaling that activates Ca2+-dependent survival pathways, thereby slowing photoreceptor loss and preserving retinal thickness.

Rationale

Recent work shows that red‑shifted microbial channelrhodopsins enable daylight‑compatible activation while reducing blue‑light phototoxicity Red‑shifted variants for safer activation. Human opsins, when expressed in inner retinal neurons, require lower irradiance, exhibit built‑in adaptation, and better preserve circuit architecture Human opsins require lower light intensity and better emulate natural adaptation. Clinical data from MCO‑010 trials demonstrate durable visual acuity gains in late‑stage RP without goggles MCO‑010 shows durable BCVA gains in late‑stage RP and mutation‑agnostic bypass of degenerated photoreceptors Eight of 11 trials target RP with mutation‑agnostic approach. Moreover, MCO‑010 exhibits neuroprotective effects in rd1/rd10 models when delivered to inner retinal neurons after photoreceptor death MCO‑010 demonstrates neuroprotective effects in mouse models. These findings suggest that optogenetic activity itself can convey protective cues, yet the potential of delivering such activity directly to stressed photoreceptors remains unexplored.

We propose that a weakly conducting human opsin expressed in rods will generate a steady, low‑level depolarization in response to ambient light. This modest Ca2+ influx can activate calmodulin‑dependent kinase II (CaMKII) and the cAMP response element‑binding protein (CREB) pathway, which are known to upregulate antioxidant genes (e.g., Nrf2 targets) and inhibit apoptosis. Importantly, the opsin’s low conductance avoids excitotoxic overload, while its red‑shifted spectrum minimizes additional phototoxic stress.

Experimental Design

1. Vector construction – AAV2‑shH10‑driven expression of a red‑shifted melanopsin variant (peak sensitivity ~620 nm) fused to a fluorescent tag; include a control AAV expressing GFP alone.
2. Animal model – rd1 mice at postnatal day 10 (early degeneration, before significant outer nuclear layer loss). Sub‑retinal injection of AAV (1 × 10^9 vg per eye).
3. Light exposure – Cyclic 12 h light/12 h dim red light (λ > 600 nm, ≤5 µW/cm²) to mimic physiological illumination without adding blue‑light stress.
4. Readouts (at 4 weeks post‑injection)
   • Outer nuclear layer thickness via OCT histology.
   • Full‑field ERG amplitudes (a‑wave and b‑wave).
   • TUNEL assay for apoptotic photoreceptors.
   • Western blot for p‑CaMKII, p‑CREB, and Nrf2 target proteins (HO‑1, NQO1).
   • Behavioral optomotor response to assess functional vision.
5. Controls – (a) GFP‑only AAV, (b) wild‑type mice with same vector, (c) rd1 mice treated with MCO‑010 AAV targeting bipolar cells (to compare inner‑vs‑outer retinal protection).

Predicted Outcomes

• Eyes receiving the photoreceptor‑targeted opsin will show significantly greater outer nuclear layer preservation (≥30 % thicker) and higher ERG a‑wave amplitudes compared with GFP controls.
• Increased p‑CaMKII/p‑CREB and Nrf2‑dependent antioxidant expression will be detected only in opsin‑treated retinas.
• TUNEL‑positive photoreceptor numbers will be reduced, correlating with improved optomotor tracking.
• No exacerbation of phototoxic damage will be observed under the red‑light regimen, confirming safety of the red‑shifted opsin.

Potential Pitfalls and Mitigations

• Over‑expression leading to calcium overload – titrate viral dose and use a weaker promoter (e.g., human synapsin minimal) to limit opsin levels.
• Off‑target transduction of neighboring cells – incorporate a photoreceptor‑specific miRNA target site (miR‑124) in the vector backbone to suppress expression in inner retinal neurons.
• Compensatory homeostatic downregulation – include a destabilizing domain (DD) fused to the opsin that can be stabilized with a low dose of Shield‑1 ligand if needed.

This hypothesis is directly testable: if tonic, low‑level optogenetic signaling in photoreceptors activates endogenous survival cascades and slows degeneration, the predicted structural, molecular, and functional improvements should be observed. Failure to detect these changes would falsify the idea that photoreceptor‑targeted optogenetic activity confers neuroprotection in early retinal disease.